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Peroxisome proliferator-activated receptor  (PPAR) is an important transcription factor in liver that can
be activated physiologically by fasting or pharmacologically by using high-affinity synthetic agonists. Here we
initially set out to elucidate the similarities in gene induction between Wy14643 and fasting. Numerous genes
were commonly regulated in liver between the two treatments, including many classical PPAR target genes,
such as Aldh3a2 and Cpt2. Remarkably, several genes induced by Wy14643 were upregulated by fasting
independently of PPAR, including Lpin2 and St3gal5, suggesting involvement of another transcription factor.
Using chromatin immunoprecipitation, Lpin2 and St3gal5 were shown to be direct targets of PPAR/ during
fasting, whereas Aldh3a2 and Cpt2 were exclusive targets of PPAR. Binding of PPAR/ to the Lpin2 and
St3gal5 genes followed the plasma free fatty acid (FFA) concentration, consistent with activation of PPAR/
by plasma FFAs. Subsequent experiments using transgenic and knockout mice for Angptl4, a potent stimulant
of adipose tissue lipolysis, confirmed the stimulatory effect of plasma FFAs on Lpin2 and St3gal5 expression
levels via PPAR/. In contrast, the data did not support activation of PPAR by plasma FFAs. The results
identify Lpin2 and St3gal5 as novel PPAR/ target genes and show that upregulation of gene expression by
PPAR/ is sensitive to plasma FFA levels. In contrast, this is not the case for PPAR, revealing a novel
mechanism for functional differentiation between PPARs.
Hepatic lipid metabolism is governed by a complex interplay
between hormones, transcription factors, and energy sub-
strates, allowing for rapid adaptations to changes in metabolic
needs (21). According to the traditional view, energy substrates
such as fatty acids influence lipid metabolism by promoting flux
through a particular pathway via mass action. However, it has
become clear that energy substrates can also directly govern
the transcription of enzymes involved in lipid metabolism via
mechanisms analogous to those of many hormones. Indeed, it
is now evident that glucose and fatty acids play a major regu-
latory role in hepatic lipid metabolism via direct activation or
inhibition of specific transcription factors, including carbohy-
drate response element binding protein (6, 63), sterol response
element binding protein 1 (SREBP1) (2, 41, 58, 61, 62), and
peroxisome proliferator-activated receptor  (PPAR) (38).
Although numerous transcription factors have been shown
to be activated by fatty acids in vitro, recent data suggest that
PPAR is dominant in mediating the effects of dietary fatty
acids on gene expression in liver (48). PPAR is a member of
the superfamily of nuclear receptors and is closely related to
the other PPAR isoforms, / and  (32). Similar to several
other nuclear receptors, PPARs function as heterodimers with
the retinoid X receptor and bind to specific sequences on the
DNA referred to as PPAR response elements (PPREs) (8, 11,
26). Numerous studies have shown that fatty acids can directly
bind to PPARs and activate DNA transcription (12, 17, 24, 28,
31, 50). Binding of fatty acids changes the conformation of the
PPAR protein (13, 23, 37, 60) and leads to recruitment of
coactivator proteins (31, 48). Besides fatty acids and their de-
rivatives, PPARs bind synthetic agonists, including the thia-
zolidionediones, which serve as agonists for PPAR, and the
fibrates, which are PPAR agonists (51).
Most of the information about the function of PPAR in
liver and its impact on target genes is based on studies that
have used high-affinity synthetic PPAR agonists. These phar-
macological studies have shown that PPAR regulates a re-
markably large number of genes, many of which are involved in
hepatic lipid metabolism, thereby explaining the positive effect
of synthetic PPAR agonists on plasma lipid parameters (9,
38). However, PPAR did not evolve as a receptor for fibrates
but rather as a fatty acid sensor. Accordingly, the question
arises to what extent results from pharmacological studies re-
flect the physiological function of PPAR.
Physiological experiments using PPAR/ mice have
shown that PPAR is especially important for the adaptive
response to fasting. During fasting, the absence of PPAR
elicits a complex phenotype characterized by fatty liver, hypo-
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ketonemia, hypoglycemia, hypothermia, and elevated plasma
free fatty acid (FFA) levels (1, 19, 27, 34). Furthermore, the
hepatic induction of numerous metabolic genes during fasting
is abolished in PPAR/ mice. While both pharmacological
and physiological studies thus support a major role for PPAR
in hepatic lipid metabolism, evidence suggests that there is
only partial overlap between genes upregulated by PPAR
during fasting and genes upregulated by synthetic PPAR ago-
nists (45). One possible explanation is that PPAR responds
differently to pharmacological compared to physiological acti-
vation. Additionally, there may be a role for other PPAR
subtypes. Besides PPAR, PPAR/ has been shown to be well
expressed in hepatocytes (10, 22). However, the functional role
of PPAR/ in hepatocytes and its physiological mechanisms
of activation remain unknown.
Here we initially set out to elucidate the similarities and
discrepancies in gene regulation in liver between pharmaco-
logical PPAR activation by Wy14643 and physiological
PPAR activation by fasting. While our data reveal major
overlap between the effects of Wy14643 and fasting, the data
also indicate that a number of pharmacological PPAR target
genes are induced by fasting independently of PPAR. Subse-
quent analysis uncovered a role for PPAR/ in hepatic gene
regulation and revealed different mechanisms of activation of
PPAR versus PPAR/ in mouse liver. Specifically, we found
that upregulation of gene expression by PPAR/ is sensitive
to plasma FFAs, while this is not the case for PPAR.
MATERIALS AND METHODS
Materials. Tridocosahexaenoin was obtained from Nu-Chek-Prep, Inc. (Ely-
sian, MN). SYBR green was purchased from Eurogentec (Seraing, Belgium).
Protease inhibitor cocktail was purchased from Roche Diagnostics (Almere, The
Netherlands), sonicated salmon sperm DNA was from Invitrogen (Breda, The
Netherlands), and proteinase K was from Fermentas (St. Leon-Rot, Germany).
All other chemicals were from Sigma (Zwijndrecht, The Netherlands).
Animals. Purebred Sv129 PPAR/ mice (129S4/SvJae) and corresponding
wild-type mice (129S1/SvImJ) were purchased from Jackson Laboratory (Bar
Harbor, ME). The PPAR// mice were on a mixed background (Sv129/
C57BL/6) and have been previously described (42). The Angptl4/, Angptl4/,
and transgenic mice were on a C57BL/6 background and have been previously
described (30, 36, 39). Angptl4-transgenic mice overexpress Angptl4 in numer-
ous tissues, including adipose tissue (36, 39), while the Angptl4/ mice lack
Angptl4 expression in all tissues (30). Only male mice were used, with 4 to 10
mice per group. For the fasting experiment, food was withdrawn for 24 h starting
at the onset of the light cycle.
PPAR ligand testing. Wild-type and PPAR/ mice were fasted for 4 h and
thereafter given an intragastric gavage of 400 l Wy14643 (10 mg/ml in 0.5%
carboxymethyl cellulose; 160 mg/kg of body weight). The control treatment was
400 l of 0.5% carboxymethyl cellulose. Livers were collected after 6 h.
Oral lipid load testing. Wild-type and PPAR/ mice were given an intra-
gastric gavage of 400 l synthetic triglyceride (tridocosahexaenoin) after a 4-hour
fast. The control treatment was 0.5% carboxymethyl cellulose (400 l). Livers
were collected 6 h after gavage.
PPAR/ ligand testing. Wild-type mice were given a single oral gavage of 150
g GW501516 (6 mg/kg). Alternatively, PPAR/ mice were fed 0.025% (wt/
wt) L165041 mixed in food for 5 days (40 mg/kg).
Mice were anesthetized with a mixture of isoflurane (1.5%), nitrous oxide
(70%), and oxygen (30%). Blood was collected by orbital puncture, after which
the mice were sacrificed by cervical dislocation. Livers were dissected and di-
rectly frozen in liquid nitrogen. For RNA analyses, tissue from the same part of
the liver lobe was used.
The animal studies were approved by the Local Committee for Care and Use
of Laboratory Animals at Wageningen University, The Netherlands, and the
University of Lausanne, Switzerland.
Affymetrix microarray. Total RNA from mouse liver was extracted with
TRIzol reagent, purified, and DNase treated using the SV total RNA isolation
system (Promega, Leiden, The Netherlands). RNA quality measurements were
performed on an Agilent 2100 bioanalyzer (Agilent Technologies, Amsterdam,
The Netherlands) using 6000 Nano Chips in combination with the eukaryote
total RNA Nano assay. RNA was judged as suitable for array hybridization only
if samples showed intact bands corresponding to the 18S and 28S rRNA subunits,
displayed no chromosomal peaks or RNA degradation products, and had an
RNA integrity number above 8.0. Five micrograms of RNA was used for the
cRNA synthesis mixture for one cycle (Affymetrix, Santa Clara, CA). Hybrid-
ization, washing, and scanning of Affymetrix mouse genome 430 2.0 arrays/
Affymetrix Nugo mouse arrays were carried out according to standard Affymetrix
protocols.
Packages from the Bioconductor Project were used for analyzing the scanned
arrays (14). Arrays were normalized using quantile normalization, and expres-
sion estimates were compiled using GC-RMA (GeneChip robust multiarray
average), applying the empirical Bayes approach (59). A nonspecific filtering step
was applied to remove genes with low variation and included only those genes
that had an interquartile range across the samples of at least 0.25 on a log2 scale
(55).
Gene set enrichment analysis (GSEA) was used to relate changes in gene
expression to functional changes between mice treated with the PPAR agonist
Wy14643 for 6 h and mice fasted for 24 h. GSEA takes into account a broad
context of physically interacting networks in which gene products function, in-
cluding biochemical, metabolic, and signal transduction routes (53). Gene sets
with a false discovery rate P value of 0.1 were considered significantly over-
represented.
Plasma metabolites. Plasma was obtained from blood by centrifugation for 10
min at 10,000 	 g. Plasma triglycerides and the glycerol concentration in cell
culture medium were determined using kits from Instruchemie (Delfzijl, The
Netherlands). Plasma free fatty acids were determined using a kit from WAKO
Chemicals (Instruchemie, Delfzijl, The Netherlands).
Fat explants. Epididymal adipose tissue was excised and cut into 0.2- to
0.3-cm3 pieces. The explants were subsequently incubated for 15 min at 37°C in
Dulbecco’s modified Eagle’s medium (DMEM) containing 1% lipid-free bovine
serum albumin (BSA) and 1 mg/ml collagenase type 1. Fat cells were liberated by
gentle stirring followed by centrifugation of the cell suspension for 1 min at
400 	 g. Fat cells were isolated from the surface and washed once in phosphate-
buffered saline (PBS). Subsequently, fat cells were incubated in DMEM con-
taining 1% lipid-free BSA and 1 M isoproterenol at 37°C with 5% CO2.
Medium was collected at various time points and frozen for measurement of free
fatty acids and glycerol (kits from Instruchemie, Delfzijl, The Netherlands).
RNA isolation and quantitative reverse transcription-PCR. Total liver RNA
was isolated with TRIzol reagent (Invitrogen) according to the manufacturer’s
instructions. A NanoDrop ND-1000 spectrophotometer (Isogen Life Science,
Ijsselstein, The Netherlands) was used to determine RNA concentrations. One
microgram of total RNA was reverse transcribed using iScript (Bio-Rad,
Veenendaal, The Netherlands). cDNA was amplified on a Bio-Rad MyIQ or
iCycler PCR machine using Platinum Taq DNA polymerase (Invitrogen). PCR
primer sequences were taken from the PrimerBank (56) and ordered from
Eurogentec. Sequences of the primers used are available upon request.
Transactivation assay. Conserved PPREs were identified at 1,291 or 23,333
nucleotides downstream of the transcriptional start site (TSS) of the mouse
Lpin2 or St3gal5 gene, respectively, using a published algorithm (20). A 201-
nucleotide and 183-nucleotide fragment surrounding the putative PPRE within
the Lpin2 and St3gal5 genes, respectively, was PCR amplified from mouse
genomic DNA (strain C57BL/6) and subcloned into the KpnI and BglII sites of
the pGL3 promoter vector (Promega, Leiden, The Netherlands). The reporter
vector (PPRE)3-TK-luciferase was included as a positive control. Reporter vec-
tors were transfected into human hepatoma HepG2 cells together with an ex-
pression vector (pSG5) for mouse PPAR/, in the presence or absence of
GW501516 (1 M). A -galactosidase reporter vector was cotransfected to
normalize for differences in transfection efficiencies. Transfections were carried
out using Nanojuice (Novagen, Nottingham, United Kingdom). Luciferase ac-
tivity was measured 24 h posttransfection using the Promega luciferase assay kit
on a Fluoroskan Ascent FL apparatus (Thermo Labsystems, Breda, The Neth-
erlands). -Galactosidase activity was measured in the cell lysate by a standard
assay using 2-nitrophenyl--D-galactopyranoside as a substrate.
For the GAL4 transactivation assay, the human osteosarcoma cell line U2OS
was maintained in DMEM Glutamax containing 10% fetal calf serum (Invitro-
gen), 100 g of penicillin/ml, and 100 g streptomycin/ml (Invitrogen). For
luciferase reporter assays, cells were seeded in 24-well plates and transiently
transfected using Lipofectamine 2000 (Invitrogen) according to the manufactur-
er’s protocol. Each well was cotransfected with 1 g of the 5	Gal4-E1BTATA-
pGL3 reporter, 10 ng of pcDNA3-GAL4-hPPARDBD, and 2 ng of pCMV-
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Renilla (Promega, Madison, WI). The next day, medium was replaced with
medium containing ligands. At 24 h after the incubation, cells were harvested in
passive lysis buffer (Promega) and assayed for luciferase activity according to the
manufacturer’s protocol (Promega dual-luciferase reporter assay system) and for
Renilla luciferase activity to correct for transfection efficiency. The relative light
units were measured by a Centro LB 960 luminometer (Berthold Technologies,
Bad Wildbad, Germany). Experiments were performed in triplicate.
Chromatin immunoprecipitation (ChIP) assay. It is becoming increasingly
apparent that most nuclear receptor binding sites, including PPREs, are not
found in proximity of the annotated TSS of a gene but are often located quite
distant (4, 33, 43). Nuclear receptors bound to such distal sites likely contact the
basal transcription machinery via DNA looping. Binding of PPAR to distant
PPREs can thus be demonstrated by showing cross-linking of PPAR to the TSS
(5, 49).
Wild-type and PPAR/ mice on an Sv129 background were fed or fasted for
24 h (n 
 3). Transgenic mice overexpressing Angptl4 (Angptl4-Tg), wild-type
mice (Angptl4/), and homozygous knockout mice (Angptl4/) (n 
 3/group)
were fasted for 24 h. At the end of the fasting period, mice were killed by cervical
dislocation and livers were extracted. Livers were cut in smaller pieces and
directly put in PBS containing 1% formaldehyde. Cross-linking was stopped after
15 min by adding glycine to a final concentration of 0.125 M for 5 min at room
temperature. After a short centrifugation to collect the liver pieces, two washing
steps with ice-cold PBS were carried out. Livers were homogenized and there-
after centrifuged. After supernatant was removed, liver homogenate was resus-
pended in lysis buffer (1% sodium dodecyl sulfate [SDS], 10 mM EDTA, 50 mM
Tris-HCl, pH 8.1, protease inhibitors), and the lysates were sonicated with a
Bioruptor (Diagenode, Lie`ge, Belgium) to achieve a DNA length of 300 to 1,000
bp. After removal of cellular debris by centrifugation, supernatants were diluted
1:10 in ChIP dilution buffer (150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 20
mM Tris-HCl, pH 7.5, protease inhibitors). Chromatin was incubated over-
night at 4°C with 2 g antibody, 25 l BSA (10 mg/ml), and 2.4 l sonicated
salmon sperm (10 mg/ml). Antibodies used were anti-PPAR (sc-9000), anti-
PPARGC1 (sc-13067), and anti-PPAR/ (sc-7197), all of which were obtained
from Santa Cruz Biotechnology (Heidelberg, Germany). Immunocomplexes
were collected with 25 l MagaCell protein A magnetic beads (Isogen Life
Science) for 1 h at room temperature and subsequently washed sequentially with
700 l of the following buffers: twice with ChIP wash buffer 1 (150 mM NaCl, 1%
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8, protease inhibitors), once
with ChIP wash buffer 2 (500 mM NaCl, 1% Triton X-100, 2 mM EDTA, 0.1%
SDS, 20 mM Tris-HCl, pH 8, protease inhibitors), once with ChIP wash buffer 3
(250 mM LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl, pH
8), and two times with TE buffer (1 mM EDTA, 10 mM Tris-HCl, pH 8). Elution
of immunocomplexes was carried out in 250 l of elution buffer (10 mM EDTA,
0.5% SDS, 25 mM Tris-HCl, pH 7.5) at 64°C for 30 min. After collection of
supernatant, elution was repeated with 250 l elution buffer at room tempera-
ture for 2 min. After combining the supernatants, cross-linking was reversed at
64°C overnight with 2.5 l proteinase K (20 mg/ml) for digestion of any remain-
ing proteins. Genomic DNA fragments were recovered by phenol-chloroform
extraction with phase lock gel (Eppendorf, Wesseling-Berzdorf, Germany), fol-
lowed by salt-ethanol precipitation. Samples were diluted in sterile H2O and
analyzed by quantitative PCR.
Primers were from Eurogentec and designed to cover the TSS of the following
genes: Aldh3a2 (forward [F], 5-CAGGTGAGGGAGCACAGTAC-3; reverse
[R], 5-CGCTTGGCTCTTTTCTGAAG-3); Cpt2 (F, 5-GCCAGTCACGCAA
CAGCAG-3; R, 5-TAGTTTAGAGACCGCTTCCG-3); Lpin2 (F, 5-CCGT
CTTGTGATTGGGCAGG-3; R, 5-GAAGGAAACTCACCAGAATCC-3);
St3gal5 (F, 5-GCCTTCCACTATCTAATCACG-3; R, 5-GTGTCCGCTCTG
CCGACTG-3); Rplp0 (F, 5-CGAGGACCGCCTGGTTCTC-3; R, 5-GTCA
CTGGGGAGAGAGAGG-3).
FAO cell culture. Rat hepatoma FaO cells were grown in DMEM containing
10% fetal bovine serum, 100 U/ml penicillin, and 100 g/ml streptomycin. Cells
were incubated with albumin only (control), albumin-bound oleic or linoleic acid
(100 M; molar ratio for FA:BSA of 3.5:1), or GW501516 (100 nM) for 4 h,
followed by RNA isolation and quantitative reverse transcription-PCR.
Cofactor recruitment assay. Nuclear receptor PamChip arrays (PamGene,
s’Hertogenbosch, The Netherlands) were used as described previously (29).
Upon binding a ligand, PPAR/ undergoes a conformational change which
promotes the formation of a cofactor binding pocket, subsequently allowing
interaction with the so-called LxxLL motif within some coregulators. The Pam-
Chip arrays consist of 53 peptides encompassing the LxxLL motifs of 22 different
coregulator proteins. Briefly, the arrays were incubated with glutathione S-
transferase-tagged PPAR/ ligand binding domain (LBD) (Invitrogen, Breda,
The Netherlands) in the presence and absence of ligand (GW501516 at 400 nM;
oleic and linoleic acids at 125 M). Quantification of the interaction between
PPAR/ and coregulators was made using Alexa 488-conjugated anti-glutathi-
one S-transferase rabbit polyclonal antibody (Invitrogen).
Microarray accession numbers. All microarray experimental results have been
deposited into the Gene Expression Omnibus database under accession number
GSE 8396 and GSE 17863.
RESULTS
Overlap in gene regulation between pharmacological and
physiological PPAR activation. PPAR in liver can be acti-
vated pharmacologically by using synthetic agonists such as
Wy14643 or physiologically by fasting. To assess the similarities
and discrepancies in gene regulation between these two stim-
uli, we compared microarray data from livers of mice treated
with the synthetic PPAR agonist Wy14643 for 6 h and livers
of mice subjected to 24 h of fasting. GSEA showed great
similarity and overlap in top-regulated pathways between fast-
ing and Wy14643 treatment, almost all of which corresponded
to pathways of lipid metabolism (Fig. 1A). Much less overlap
was observed at the individual gene level (Fig. 1B). Neverthe-
less, a substantial number of genes upregulated by Wy14643
were also induced by fasting. Many of these genes represent
classical PPAR target genes involved in fatty acid catabolism,
such as Acox1, Cpt2, Aldh3a2, Acot8, Ehhadh, and Hmgcs2.
Consistent with an important role of PPAR, induction of
classical PPAR target genes by fasting was abolished in
PPAR/ mice (Fig. 1C and D). In contrast, a number of
Wy14643-responsive genes could be identified that were more
significantly upregulated by fasting in PPAR/ mice than in
wild-type mice, suggesting PPAR-independent regulation
during fasting (Fig. 1C and D). Overall, these data indicate
that targets of pharmacological PPAR activation exhibit di-
verse responses following physiological PPAR activation by
fasting, being either up- or downregulated and showing a vari-
able dependence on PPAR.
To explore the possible mechanism underlying the more
significant induction by fasting of a number of pharmacological
PPAR targets in PPAR/ mice compared to wild-type
mice, two representative genes were investigated in more de-
tail: Lpin2 and St3gal5. Remarkably, in contrast to classical
PPAR targets Cpt2 and Aldh3a2 (Fig. 2A and C), induction
of Lpin2 and St3gal5 by fasting and dietary fatty acids was
largely maintained in PPAR/ mice (Fig. 2B and D). These
results imply that the effects of fasting and dietary fatty acids
on hepatic expression of Lpin2 and St3gal5 may be partially
mediated by a transcription factor other than PPAR. On the
contrary, effects of fasting and dietary fatty acids on Cpt2 and
Aldh3a2 are entirely mediated by PPAR. It should be men-
tioned that the expression profiles of Cpt2 and Aldh3a2 are rep-
resentative of a large set of classical PPAR targets (Fig. 1D).
PPAR/ as an alternative transcription factor to PPAR
in mouse liver during fasting. One obvious candidate alterna-
tive transcription factor is PPAR/, which is well expressed in
liver (10, 16). Supporting regulation of Lpin2 and St3gal5 by
PPAR/, the PPAR/ agonists GW501516 and L165041 sig-
nificantly induced Lpin2 and St3gal5 mRNA (Fig. 3A). To
establish whether Lpin2 and St3gal5 are direct PPAR target
genes, we identified a conserved PPRE within the Lpin2 and
St3gal5 genes (Fig. 3B) and cloned a genomic region encom-
passing the PPRE in front of a luciferase reporter to perform
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transactivation assays. GW501516 significantly increased re-
porter activity for the Lpin2 and St3gal5 genomic regions,
which was further enhanced by cotransfection with PPAR/
(Fig. 3C). In subsequent ChIP experiments, PPAR/ as well
as PPAR could be cross-linked to the TSS of the Lpin2 and
St3gal5 genes, at least in the fasted state, which provided evi-
dence for the presence of a distant functional PPRE (Fig. 3D).
These data suggest that Lpin2 and St3gal5 genes represent direct
PPAR target genes. Interestingly, while fasting increased bind-
ing of both PPAR and PPAR/ to the Lpin2 and St3gal5
genes, fasting increased binding of only PPAR to the Aldh3a2
and Cpt2 genes (Fig. 3D). No binding of PPAR and PPAR/
to the negative control gene Rplp0 was observed. All together
these data suggest that Lpin2 and St3gal5 are dual targets of
PPAR and PPAR/, whereas Aldh3a2 and Cpt2 are exclu-
sive targets of PPAR. In agreement with this notion, induc-
tion of Lpin2 and St3gal5 by fasting was partially abolished in
PPAR// mice (Fig. 3E).
Given the more pronounced induction of Lpin2 and St3gal5
by fasting in PPAR/ versus wild-type mice, we speculated
that either expression of PPAR/ may be upregulated in
PPAR/ mice as a compensatory mechanism or that ligand
activation of PPAR/ is enhanced in PPAR/ mice. While
we could not detect a change in PPAR/ mRNA in
PPAR/ mice (data not shown), consistent with the second
scenario, plasma FFA levels were markedly elevated in fasted
PPAR/ mice (Fig. 3F), which was associated with marked
induction of PPAR/ binding to the Lpin2 and St3gal5 pro-
moter (Fig. 3D). These data suggest that in the absence of
PPAR plasma FFAs can induce Lpin2 and St3gal5 expression
via PPAR/. It should be noted that levels of plasma FFAs
during fasting are unaltered in PPAR// mice (Fig. 3G).
FIG. 1. Hepatic genes activated by Wy14643 and fasting show a variable dependence on PPAR. Livers from wild-type and PPAR/ mice
treated with the PPAR agonist Wy14643 for 6 h or fasted for 24 h were used for gene expression profiling (n
 4 to 5 mice per group). (A) Overlap
in top-regulated pathways between Wy14643 treatment and fasting according to gene set enrichment analysis. Gene sets with a false discovery rate
P value of 0.1 were considered significant. (B) Overlap of upregulated genes between Wy14643 treatment and fasting (criteria for inclusion: P
 0.01 and a change of 1.5-fold). (C) Scatter plot showing the effects of fasting in genes significantly upregulated by Wy14643. The y axis and
x axis show the effects of fasting in wild-type and PPAR/ mice, respectively. Red dots represent classical PPAR target genes, while blue dots
are Wy14643-responsive genes that are more significantly upregulated by fasting in the PPAR/ mouse compared to wild type. (D) Heatmap
showing the changes (n-fold) of genes compared to the wild-type control/fed state. (Upper panel) Classical PPAR target genes, showing a
PPAR-dependent increase in gene expression upon Wy14643 treatment as well as fasting. Genes in the lower panel exhibit a PPAR-dependent
induction upon Wy14643 treatment but are induced independently of PPAR upon fasting.
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Circulating FFAs activate PPAR/ but not PPAR in mouse
liver. Importantly, recent evidence suggests that PPAR in
liver cannot be (ligand) activated by plasma FFAs, while it can
be activated by fatty acids synthesized de novo (3). To study the
activation of PPAR and PPAR/ by plasma FFAs, we mod-
ulated fasting plasma FFA levels by taking advantage of a
unique transgenic model system based on whole-body overex-
pression or inactivation of the mouse Angptl4 gene, which
encodes a prolipolytic factor involved in lipid metabolism (39,
52). Previously, intravenous injection of Angptl4 was shown to
cause an immediate increase in plasma FFA (65). In support,
Angptl4 increased release of glycerol from 3T3-L1 adipocytes
(Fig. 4A).
Consistent with a prolipolytic effect of Angptl4, Angptl4
overexpression in mice was associated with a significant in-
crease in release of fatty acids and glycerol from adipose tissue,
whereas the opposite was observed in Angptl4/ mice (Fig.
4B). In agreement with these data, fasting plasma FFA levels
were increased or decreased upon Angptl4 overexpression or
inactivation, respectively (Fig. 4C). In fact, the fasting-induced
increase in plasma FFA was entirely blunted in Angptl4/
mice. Plasma triglyceride levels were increased or decreased
upon Angptl4 overexpression or inactivation (Fig. 4D), respec-
tively, reflecting the well-documented inhibitory effect of Angptl4
on lipoprotein lipase activity (25). Finally, the defective lipol-
ysis in Angptl4/ and Angptl4/ mice was supported by the
absence of changes in adipocyte cell size upon fasting, in con-
trast to Angptl4-Tg and wild-type mice (Fig. 4E). These results
corroborate the stimulatory effect of Angptl4 on adipose tissue
lipolysis, which we exploited to study the effect of plasma FFAs
on hepatic gene expression.
If hepatic PPAR is activated by plasma FFAs, expression of
classical PPAR target genes during fasting would be expected to
be proportional to the plasma FFA level throughout the various
Angptl4 mouse models. Remarkably, rather than going down,
gene expression of classical PPAR targets Aldh3a2, Cpt2, and
others was stable or went up as plasma FFAs declined (Fig. 5A;
see also Fig. S1A in the supplemental material). Expression of
Ppar itself, which is auto-regulated, followed a very similar pat-
tern (Fig. 5B), suggesting that regulation of classical PPAR
targets is determined by PPAR expression level. Supporting
the use of the Angptl4 mouse models to study hepatic gene
regulation by FFA, hepatic expression of Srebp1, which is
known to be suppressed by fatty acids, negatively correlated
with plasma FFA concentration (data not shown). In combi-
nation with previously published data (3), these data strongly
suggest that PPAR is not activated by plasma FFA in mouse
liver.
While plasma FFAs seemingly do not activate hepatic
PPAR, data presented above suggested that plasma FFAs
induce Lpin2 and St3gal5 expression by activating PPAR/, at
least when PPAR is absent. In order to explore activation of
hepatic PPAR/ by plasma FFA, we first determined that
fatty acids are able to bind and activate PPAR/ in vitro. In
a transactivation assay using the GAL4-LBDPPAR/ fusion,
oleic and linoleic acids markedly induced luciferase activity,
indicating activation of PPAR/ (Fig. 5C). Next we studied
the effects of oleic and linoleic acids on the interaction between
PPAR/ and peptides corresponding to specific coregulator-
nuclear receptor binding regions (29). Both fatty acids and
GW501516 promoted the interaction between PPAR/ and
numerous coregulator peptides, which demonstrated their bind-
ing to PPAR/ (Fig. 5D). Finally, oleic and linoleic acids
significantly induced expression of the PPAR/ marker gene
Adfp in hepatoma cells (Fig. 5E). These data demonstrate that
fatty acids directly activate PPAR/. To assess activation of
PPAR/ in vivo by circulating FFAs in the presence of
PPAR, we determined binding of PPAR/ to the Lpin2 and
St3gal5 genes in the Angptl4 mouse models by using ChIP.
Importantly, independent of PPAR/ gene expression levels,
FIG. 2. Lpin2 and St3gal5 are induced during fasting independently of PPAR. Livers from wild-type and PPAR/ mice fasted for 24 h or
treated with tridocosahexaenoin (DHA) for 6 h were used for gene expression profiling (n 
 4 to 5 mice per group). (A and B) Gene expression
of classical PPAR targets Aldh3a2 and Cpt2 (A) and Lpin2 and St3gal5 (B) in fed and fasted wild-type and PPAR/ mice. (C and D) Gene
expression of Aldh3a2 and Cpt2 (C) and Lpin2 and St3gal5 (D) after treatment with the dietary fatty acid tridocosahexaenoin. Error bars represent
standard errors of the means. *, significantly different according to Student’s t test (P  0.05).
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which remained constant (Fig. 5F), binding of PPAR/ to the
Lpin2 and St3gal5 genes was proportional to the plasma FFA
concentration and mimicked fasting Lpin2 and St3gal5 expres-
sion levels (Fig. 5G and H). In contrast, binding of PPAR to
the Lpin2 and St3gal5 genes was minimal and did not follow
the plasma FFA concentration (Fig. 5G). Again, no binding of
PPAR and PPAR/ to the negative control gene Rplp0 was
observed. These data suggest that PPAR/ can be activated
by plasma FFAs. Other Wy14643-induced genes whose expres-
sion followed the plasma FFA concentration independent of
PPAR included lipid droplet proteins 2310076L09Rik (MLDP),
and S3-12, as well as Slc16a5 and Gadd45b, suggesting they
might represent targets of PPAR/ as well (see Fig. S1B in
the supplemental material).
PPAR target genes may be upregulated during fasting via
induction of PGC1. If elevated plasma FFAs cannot ac-
count for the induction of classical PPAR activation during
fasting, the question arises what other mechanism may be
responsible. One possibility is increased coactivator expres-
sion. The coactivator PPAR coactivator 1 (PGC1) plays a
major role in the liver during fasting by upregulating genes
involved in gluconeogenesis and fatty acid oxidation/keto-
genesis, mediating activation by several transcription fac-
tors, including PPAR (47, 54, 64). In agreement with pre-
FIG. 3. PPAR/ as alternative transcription factor to PPAR in mouse liver. (A) Lpin2 and St3gal5 expression in livers of wild-type mice (n

5) treated with the PPAR/ agonist GW501516 for 6 h or PPAR/ mice (n 
 5) treated with the PPAR/ agonist L165041 for 5 days. Error
bars represent standard errors of the means. (B) PPREs conserved between mouse and human were identified 1,291 bp and 23,333 bp downstream
of the TSS of the Lpin2 and St3gal5 genes. (C) HepG2 cells were transfected with a PPAR/ expression vector and a simian virus 40 reporter
vector containing 201-nucleotide and 183-nucleotide fragments with the putative PPREs within the Lpin2 and St3gal5 genes, respectively. The
reporter vector (PPRE)3-TK-luciferase served as a positive control. Luciferase and -galactosidase activities were determined 24 h after exposure
of the cells to 1 M GW501516. Error bars represent standard errors of the means. (D) Chromatin was extracted from livers of fed or 24-h-fasted
wild-type and PPAR/ mice (n
 3 per group). ChIP was performed with antibodies against PPAR and PPAR/ on the TSS of Lpin2, St3gal5,
Aldh3a2, Cpt2, and Rplp0. Rabbit IgG was used as a specificity control. Gray bars, fed state; black bars, 24-h fasted state. Error bars represent
standard deviations. (E) Expression of Lpin2 and St3gal5 in livers of fed and 24-h-fasted wild-type and PPAR// mice (n 
 4 to 5 per group).
Relative induction by fasting is indicated. Error bars represent standard errors of the means. (F and G) Plasma FFA levels in wild-type and
PPAR/ mice (F) or wild-type and PPAR// mice (G) sacrificed in a fed or 24-h-fasted state. Error bars represent standard errors of the
means. *, significantly different according to Student’s t test (P  0.05).
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vious data (64), expression of Pgc1a went up significantly
during fasting (Fig. 6A). Importantly, fasting markedly en-
hanced binding of PGC1 to the TSS of the PPAR target
genes Aldh3a2 and Cpt2, which was abolished in PPAR/
mice (Fig. 6B). No binding of PGC1 to Rplp0 was ob-
served. These data suggest that upregulation of Pgc1
mRNA may contribute to induction of classical PPAR
target genes during fasting via increased PPAR-dependent
binding of PGC1 to gene promoters.
DISCUSSION
It has been clearly established that PPAR governs the
fasting-induced upregulation of numerous genes involved in
hepatic fatty acid oxidation, many of which are direct PPAR
target genes (19, 27, 34). However, it has remained unclear
whether elevated plasma FFAs themselves are responsible for
the induction of hepatic fatty acid catabolism via enhanced
ligand activation of PPAR (19, 27, 34). Recently, using mice
FIG. 4. Angptl4 stimulates adipose tissue lipolysis. (A) Glycerol concentration in medium of 3T3-L1 cells treated for 30 min with isoproterenol
or with concentrated conditioned medium of HEK293 cells transfected with mAngptl4. Control cells were treated with conditioned medium of
nontransfected HEK293 cells. Error bars represent standard errors of the means. *, significantly different according to Student’s t test (P  0.05).
(B) Increase in fatty acid and glycerol concentrations in medium of adipose tissue explants from transgenic mice overexpressing Angptl4 (Tg),
wild-type (/), and homozygous knockout (/) mice. Values are corrected for weight of explants. (C and D) Plasma FFAs (C) and triglycerides
(D) in transgenic mice overexpressing Angptl4 (Angptl4-Tg) and wild-type (Angptl4/), heterozygous (Angptl4/), and homozygous (Angptl4/)
mice fed or in a 24-h-fasted state (n 
 5). Gray bars, fed state; black bars, 24-h-fasted state. Error bars represent standard errors of the means.
Different letters indicate statistically significant differences (Student’s t test; P  0.05). (E) Eosin and hematoxylin staining of epididymal adipose
tissue.
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FIG. 5. Plasma FFAs do not activate hepatic PPAR. Transgenic mice overexpressing Angptl4 (Angptl4-Tg) or wild-type (Angptl4/), heterozygous
(Angptl4/), and homozygous knockout (Angptl4/) mice were sacrificed in the fed state or after a 24-h fast (n 
 5). Results show hepatic gene expression
of classical PPAR targets Aldh3a2 and Cpt2 (A), Ppar (B), and Ppar/ (F). Gray bars, fed state; black bars, 24-h-fasted state. Error bars represent standard
errors of the means. *, P  0.05. (C) Fatty acids activate PPAR/ in a transactivation assay using a GAL4-LBDPPAR/ fusion. Fatty acids were used at 125
M or 250 M (normal or bold plus sign). (D) A nuclear receptor PamChipH assay was used to measure the interaction between PPAR/ and immobilized
peptides corresponding to specific coregulator-nuclear receptor binding regions in the presence and absence of fatty acids (125 M). (E) Fatty acids (100 M)
upregulated expression of PPAR/ target Adfp in rat FaO hepatoma cells. (G) Chromatin was extracted from livers of 24-h-fasted transgenic mice overex-
pressing Angptl4 (Tg) and wild-type (/) and homozygous Angptl4 knockout (/) mice (n 
 3 per group). ChIP was performed with antibodies against
PPAR and PPAR/ on the TSS ofLpin2, St3gal5, andRplp0. Rabbit IgG was used as a specificity control. Error bars represent standard deviations. Different
lowercase letters indicate statistically significant differences (Student’s t test; P 0.05). (H) Hepatic gene expression of Lpin2 and St3gal5. Gray bars, fed state;
black bars, 24-h-fasted state. Error bars represent standard errors of the means. Different lowercase letters indicate statistically significant differences (Student’s
t test; P  0.05).
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with liver-specific inactivation of the Fasn gene, Chakravarthy
et al. showed that unlike dietary fatty acids and de novo-
synthesized fatty acids, circulating FFAs fail to activate hepatic
PPAR (3). In the present study, by using mice differentially
expressing Angptl4 we arrived at essentially the same conclu-
sion.
Importantly, our data also suggest that in contrast to PPAR,
hepatic PPAR/ can be activated by plasma FFA, which ac-
counts for the plasma FFA- and fasting-dependent upregula-
tion of several genes in wild-type and PPAR/ mice, includ-
ing Lpin2 and St3gal5. Indeed, we demonstrated that Lpin2
and St3gal5 expression and binding of PPAR/ to the Lpin2
and St3gal5 promoter closely mirror plasma FFA levels. The
role of PPAR/ in gene regulation by plasma FFA during
fasting was substantiated by the observation that induction of
Lpin2 and St3gal5 by fasting is reduced in PPAR// mice.
In contrast to plasma FFAs, evidence abounds indicating
that dietary fatty acids are able to activate PPAR (40, 44, 46).
Recently, it was shown that the effects of dietary fatty acids on
hepatic gene expression are quantitatively almost entirely me-
diated by PPAR (48). Additionally, the present data suggest
that dietary fatty acids can also activate PPAR/, as induction
of Lpin2 and St3gal5 by dietary fat was entirely or partially
maintained in PPAR/ mice.
It may be argued that the lack of effect of declining plasma
FFAs on hepatic PPAR activation may be because PPAR,
in contrast to PPAR/, is already saturated with fatty acids at
low plasma FFA levels, thus allowing no further activation.
Previously, it has been shown that fatty acids bind to PPAR/
with an about 5- to10-fold-lower affinity than to PPAR (60).
However, as treatment with synthetic agonists clearly results in
more pronounced PPAR activation compared to fasting (44),
the argument of PPAR saturation is only tenable if we as-
sume fatty acids act as partial agonists that do not elicit full
PPAR activity compared to synthetic agonists. Saturation of
PPAR is also not supported by the findings reported by
Chakravarthy et al. (3).
Alternatively, it is conceivable that fatty acids are present in
hepatocytes in distinct pools which have different activities
toward PPAR and PPAR/. In this context, it should be
realized that dietary fatty acids present in chylomicron rem-
nants are internalized differently compared to plasma FFAs.
Whereas the former are liberated after endosomal and lysoso-
mal degradation of cholesteryl esters and triglycerides, plasma
FFAs are likely internalized via diffusion as well as via specific
fatty acid transport proteins, including CD36. The third con-
tributor to the hepatic fatty acid pool is de novo lipogenesis, a
process which occurs in the cytosol. It is presently unclear to
what extent these three sources of fatty acids undergo similar
metabolic fates. Recent studies support the existence of dis-
tinct hepatic fatty acid pools that are differentially shuttled into
various metabolic pathways, including oxidation and incorpo-
ration into very-low-density lipoprotein (VLDL) triglycerides
(67). For example, there is evidence that fatty acids generated
by de novo lipogenesis only marginally contribute to VLDL
triglycerides, in contrast to plasma FFAs (15). Our present and
previous data suggest that in terms of gene regulation, a similar
type of segregation occurs between the three sources of fatty
acids (3). The mechanism underlying the differential activity of
fatty acids from distinct pools toward PPAR and PPAR/
remains unknown. One could hypothesize a role for fatty acid
binding proteins (FABPs). It can be speculated that FABP1,
which has been shown to interact with PPAR (57), picks up
lipoprotein-derived fatty acids and shuttles them to PPAR,
whereas another FABP expressed in liver such as FABP2 may
selectively bind free fatty acids coming from plasma and shuttle
them to PPAR/.
An important lingering question is that if plasma FFAs do
not activate hepatic PPAR during fasting, what mechanism
accounts for activation of PPAR-dependent gene regulation
during fasting? Previously, a role for PGC1 in fasting-depen-
dent upregulation of hepatic mitochondrial fatty acid oxidation
and ketogenesis was shown (47, 54). Our ChIP analysis indi-
cates enhanced recruitment of PGC1, which itself is upregu-
lated by fasting, to classical PPAR target genes during fasting.
Accordingly, activation of PPAR by fasting may be driven by
the increase in PGC1 expression, although an important role
for other coactivators cannot be excluded. Recently, it was
shown that PGC1 cooperates with BAF60a (SMARCD1) to
activate transcription of PPAR target genes involved in per-
oxisomal and mitochondrial fatty acid oxidation genes (35).
While our data suggest that PPAR/mediates the effects of
plasma FFAs on a small set of genes in the liver, the overall
importance of PPAR/ in hepatic gene regulation by FFAs
remains unclear. The same is true for the actual functional
role of PPAR/ in liver. Presently, combined transcriptom-
FIG. 6. PPAR activation during fasting may be mediated by PGC1 upregulation. (A) Expression of Pgc1a in livers of fed or fasted wild-type
mice (n 
 5). Fasting statistically significantly induced gene expression of Pgc1 (P  0.05). Error bars represent standard errors of the means.
(B) Chromatin was extracted from livers of fed and 24-h-fasted wild-type and PPAR/ mice (n 
 3 per group). ChIP was performed with
antibodies against PGC1 on the TSS of Aldh3a2 and Cpt2 and the negative control gene Rplp0. Rabbit IgG was used as a specificity control. Gray
bars, fed state; black bars, 24-h-fasted state. Error bars represent standard deviations. Fasting significantly induced binding of PGC1 in wild-type
but not PPAR/ mice (P  0.05).
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ics and metabolomics analyses of livers of PPAR/ and
PPAR// mice are under way to gain more understanding
about the role of PPAR/ in the liver and to determine the
extent to which PPAR and PPAR/ regulate distinct sets of
genes and govern distinct metabolic pathways, especially under
physiological circumstances.
In this study we have used variable expression of the Angptl4
gene to create variations in fasting plasma FFA levels in mice.
Angptl4 is a potent inhibitor of lipoprotein lipase and hepatic
lipase and decreases uptake of lipoprotein remnants by the
liver, thereby decreasing hepatic uptake of dietary fatty acids
(36). In addition, it stimulates adipose tissue lipolysis, as shown
by the acute increase in plasma FFA upon injection of recom-
binant Angptl4 (65) and by elevated plasma FFAs and glycerol
levels in mice overexpressing Angptl4 (39). The prolipolytic
effect of Angptl4 is supported by recent data in humans (52). In
the present paper, Angptl4 markedly induced glycerol release
from 3T3-L1 adipocytes. Activation of lipolysis by Angptl4 was
further substantiated by the altered release of fatty acids and
glycerol from adipose tissue explants from Angptl4-Tg and
Angptl4/ mice, as well as by the lack of an increase in FFA
during fasting in Angptl4/ mice. As a consequence, hepatic
VLDL production is reduced in Angptl4/ mice (7). By in-
hibiting lipoprotein lipase and stimulating adipose tissue lipol-
ysis, Angptl4 promotes switching of hepatic fatty acid uptake
from remnant-derived fatty acids toward plasma FFAs (39).
Importantly, the variations in plasma FFAs in the Angptl4
mouse models are specifically elicited by fasting, permitting
study of the impact of differential plasma FFAs on hepatic
gene expression during fasting.
While in vivo and in vitro studies using synthetic PPAR
agonists are extremely relevant to assess the toxicological and
pharmacological impacts and significance of PPAR, it is un-
clear to what extent they report on the physiological role of
PPAR in liver. Our results reveal that several genes upregu-
lated following pharmacological PPAR activation are not in-
duced by PPAR under physiological conditions such as fast-
ing, or are induced by fasting independently of PPAR but are
dependent on PPAR/. It is well known that in reporter
assays PPAR and PPAR/ (and PPAR) can activate the
same genes, suggesting that all PPARs share an intrinsic ability
to transactivate any given PPAR target gene. The present data
on Lpin2 and St3gal5 are consistent with the notion that in vivo
the dominant receptor in the regulation of a particular PPAR
target is context dependent and importantly may differ be-
tween pharmacological and physiological stimuli. Genes other
than Lpin2 and St3gal5 that have been shown to be activated by
both PPAR and PPAR/ include Adfp (18), G0s2 (66), and
Pdk4 (5). Overall, the data imply that studies using high-affinity
synthetic PPAR agonists are not perfectly suited to assess the
functions of PPARs during normal physiology.
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